Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Medicure (MCUJF) Research & Development (2016 - 2025)

Medicure has reported Research & Development over the past 17 years, most recently at $825366.3 for Q4 2025.

  • For Q4 2025, Research & Development rose 255.39% year-over-year to $825366.3; the TTM value through Dec 2025 reached $414332.3, down 65.12%, while the annual FY2025 figure was $2.3 million, 3.36% up from the prior year.
  • Research & Development for Q4 2025 was $825366.3 at Medicure, up from $520997.3 in the prior quarter.
  • Over five years, Research & Development peaked at $1.0 million in Q2 2022 and troughed at -$567998.0 in Q4 2022.
  • A 5-year average of $173141.8 and a median of $375358.1 in 2021 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: surged 711.48% in 2021 and later crashed 1804.67% in 2022.
  • Year by year, Research & Development stood at $33320.1 in 2021, then tumbled by 1804.67% to -$567998.0 in 2022, then grew by 0.29% to -$566326.9 in 2023, then grew by 6.21% to -$531160.1 in 2024, then skyrocketed by 255.39% to $825366.3 in 2025.
  • Business Quant data shows Research & Development for MCUJF at $825366.3 in Q4 2025, $520997.3 in Q3 2025, and -$534789.0 in Q2 2025.